Klaus Podar

18.1k total citations · 3 hit papers
186 papers, 12.8k citations indexed

About

Klaus Podar is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Klaus Podar has authored 186 papers receiving a total of 12.8k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Molecular Biology, 129 papers in Hematology and 64 papers in Oncology. Recurrent topics in Klaus Podar's work include Multiple Myeloma Research and Treatments (121 papers), Protein Degradation and Inhibitors (34 papers) and Ubiquitin and proteasome pathways (30 papers). Klaus Podar is often cited by papers focused on Multiple Myeloma Research and Treatments (121 papers), Protein Degradation and Inhibitors (34 papers) and Ubiquitin and proteasome pathways (30 papers). Klaus Podar collaborates with scholars based in United States, Germany and Austria. Klaus Podar's co-authors include Kenneth C. Anderson, Dharminder Chauhan, Teru Hideshima, Paul G. Richardson, Nikhil C. Munshi, Constantine S. Mitsiades, Noopur Raje, Yu‐Tzu Tai, Martin Sattler and Nicholas Mitsiades and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Klaus Podar

183 papers receiving 12.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

2001 740 citations Noopur Raje, Teru Hideshima et al. Blood profile →
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

2005 560 citations Dharminder Chauhan, Klaus Podar et al. profile →
Multiple myeloma

2009 533 citations Marc S. Raab, Klaus Podar et al. profile →

Peers

Countries citing papers authored by Klaus Podar

Since Specialization

Citations

This map shows the geographic impact of Klaus Podar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Podar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Podar more than expected).

Fields of papers citing papers by Klaus Podar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Podar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Podar. The network helps show where Klaus Podar may publish in the future.

Co-authorship network of co-authors of Klaus Podar

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Podar. A scholar is included among the top collaborators of Klaus Podar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Podar. Klaus Podar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	PARP7 as a new target for activating anti-tumor immunity in cancer 2025 ·EMBO Molecular Medicine ·(unknown), (unknown), (unknown), Carola Lütgendorf‐Caucig, Piero Fossati, Joachim Widder, Klaus Podar, Dea Slade	4
2	Favorable impact of PD1/PD-L1 antagonists on bone remodeling: an exploratory prospective clinical study and ex vivo validation 2024 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), Benjamin Neuditschko, Klaus Hackner, (unknown), (unknown), (unknown), (unknown), Franz Herzog, Christoph Wiesner, Peter Errhalt, Martin Pecherstorfer, Klaus Podar, Sonia Vallet	6
3	Dual therapeutic targeting of MYC and JUNB transcriptional programs for enhanced anti-myeloma activity 2024 ·Blood Cancer Journal ·Judith Lind, (unknown), Michaela Prchal‐Murphy, Fengjuan Fan, Mariateresa Fulciniti, Dagmar Stoiber, Latifa Bakiri, Erwin F. Wagner, (unknown), Martin Sattler, Karoline Kollmann, Sonia Vallet, Klaus Podar	3
4	Tissue Hypoxia and Alterations in Microvascular Architecture Predict Glioblastoma Recurrence in Humans 2020 ·Clinical Cancer Research ·Andreas Stadlbauer, Thomas M. Kinfe, Ilker Y. Eyüpoglu, Max Zimmermann, Melitta Kitzwögerer, Klaus Podar, Michael Buchfelder, Gertraud Heinz‐Peer, Stefan Oberndorfer, Franz Marhold	24
5	GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor Cell Growth In Vitro and In Vivo 2012 ·Cancer Research ·Marc S. Raab, Iris Breitkreutz, Simon Anderhub, Mads H. Rønnest, (unknown), Thomas Ostenfeld Larsen, Ludmila Weiz, (unknown), Patrick Hayden, Klaus Podar, Johannes Fruehauf, (unknown), Walter Mier, Uwe Haberkorn, Anthony D. Ho, Hartmut Goldschmidt, Kenneth C. Anderson, Mads H. Clausen, Alwin Krämer	56
6	Novel Oncogenic Mutations of CBL in Human Acute Myeloid Leukemia That Activate Growth and Survival Pathways Depend on Increased Metabolism 2010 ·Journal of Biological Chemistry ·(unknown), Mamatha M. Reddy, Nicole J. Croteau, Christoph Walz, (unknown), Klaus Podar, Hamid Band, Martin Carroll, Andreas Reiter, Richard A. Larson, Ravi Salgia, James D. Griffin, Martin Sattler	39
7	CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells (Blood (2009) 113, 18, (4309-4318)) 2010 ·Blood ·(unknown), Ender Soydan, Wentao Song, Mariateresa Fulciniti, (unknown), Fei Hong, (unknown), Patrick Burger, (unknown), Saifun Nahar, Klaus Podar, Teru Hideshima, (unknown), Giovanni Tonon, Ruben D. Carrasco, Daniel Afar, K. C. Anderson	5
8	Targeting Angiogenesis via a c-Myc/Hypoxia-Inducible Factor-1α–Dependent Pathway in Multiple Myeloma 2009 ·Cancer Research ·Jing Zhang, Martin Sattler, Giovanni Tonon, Clemens Grabher, Samir Lababidi, (unknown), Marc S. Raab, Sonia Vallet, Yiming Zhou, (unknown), Teru Hideshima, Yu‐Tzu Tai, Dharminder Chauhan, Kenneth C. Anderson, Klaus Podar	76
9	Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma 2007 ·Cancer Research ·Klaus Podar, Marc S. Raab, Giovanni Tonon, Martin Sattler, Daniela Barilá, Jing Zhang, Yu‐Tzu Tai, Hiroshi Yasui, Noopur Raje, Ronald A. DePinho, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson	55
10	The therapeutic role of targeting protein kinase C in solid and hematologic malignancies 2007 ·Expert Opinion on Investigational Drugs ·Klaus Podar, Marc S. Raab, Dharminder Chauhan, Kenneth C. Anderson	46
11	Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma 2007 ·Expert Review of Anticancer Therapy ·Klaus Podar, Paul G. Richardson, Dharminder Chauhan, Kenneth C. Anderson	10
12	Effects of PKC412, Nilotinib, and Imatinib Against GIST-Associated PDGFRA Mutants With Differential Imatinib Sensitivity 2006 ·Gastroenterology ·Ellen Weisberg, Renee D. Wright, Jingrui Jiang, Arghya Ray, Daisy Moreno, Paul W. Manley, Doriano Fabbro, Elizabeth Hall–Meyers, Laurie Catley, Klaus Podar, Andrew L. Kung, James D. Griffin	75
13	Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-β inhibitors 2005 ·Oncogene ·Teru Hideshima, Dharminder Chauhan, Kenji Ishitsuka, Hiroshi Yasui, Noopur Raje, Shaji Kumar, Klaus Podar, Constantine S. Mitsiades, Hiromasa Hideshima, Lynn Bonham, Nikhil C. Munshi, Paul G. Richardson, Jack W. Singer, Kenneth C. Anderson	41
14	Immunomodulatory Drug Lenalidomide (CC-5013, IMiD3) Augments Anti-CD40 SGN-40–Induced Cytotoxicity in Human Multiple Myeloma: Clinical Implications 2005 ·Cancer Research ·Yu‐Tzu Tai, Xianfeng Li, Laurence Catley, Rory Coffey, Iris Breitkreutz, Jooeun Bae, Weihua Song, Klaus Podar, Teru Hideshima, Dharminder Chauhan, Robert Schlossman, Paul G. Richardson, Steven P. Treon, Iqbal S. Grewal, Nikhil C. Munshi, Kenneth C. Anderson	132
15	Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application 2004 ·British Journal of Haematology ·Toshiaki Hayashi, Teru Hideshima, Masaharu Akiyama, Klaus Podar, Hiroshi Yasui, Noopur Raje, Shaji Kumar, Dharminder Chauhan, Steven P. Treon, Paul G. Richardson, Kenneth C. Anderson	267
16	Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of b1-integrin and phosphatidylinositol 3-kinase/AKT signaling beta. 2003 ·Blood ·YT Tai, Klaus Podar, (unknown), (unknown), Reshma Shringarpure, Renate Burger, Masaharu Akiyama, Teru Hideshima, D Chauhan, Nicholas Mitsiades, Paul Richardson, (unknown), C.Ronald Kahn, Constantine S. Mitsiades, KC Anderson	33
17	Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. 2003 ·PubMed ·Teru Hideshima, Dharminder Chauhan, Toshiaki Hayashi, Klaus Podar, Masaharu Akiyama, Constantine Mitsiades, Nicholas Mitsiades, Baoqing Gong, Lynn Bonham, Peter de Vries, Nikhil C. Munshi, Paul G. Richardson, Jack W. Singer, Kenneth C. Anderson	58
18	Gene expression analysis of tumor cells sensitive and resistant to PS-341 (Bortezomib) treatment: Clinical implications. 2003 ·Blood ·Reshma Shringarpure, D Chauhan, Renate Burger, (unknown), YT Tai, Klaus Podar, Teru Hideshima, Nicholas Mitsiades, C Mitsiades, KC Anderson	1
19	Targeting mitochondria to overcome conventional and Bortezomib-resistance in multiple myeloma cells. 2003 ·Blood ·D Chauhan, (unknown), Klaus Podar, Teru Hideshima, M. Kelly Nicholas, (unknown), Laurence Catley, (unknown), KC Anderson	2
20	Heat shock protein-27 confers drug-resistance in multiple myeloma cells. 2002 ·Blood ·D Chauhan, (unknown), Teru Hideshima, Klaus Podar, (unknown), Richard LeBlanc, Nicholas Mitsiades, C Mitsiades, PG Richardson, Satya Saxena, KC Anderson	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact